尤瑞克林联合巴曲酶治疗急性大脑中动脉脑梗死的近期临床疗效观察

Therapeutic effect of Urinary Kallidinogenase plus Bathoxobin on acute middle cerebral artery infarction

目的探讨尤瑞克林联合巴曲酶治疗急性大脑中动脉脑梗死的近期疗效和安全性。方法选择急性大脑中动脉脑梗死患者92例,随机分为联合治疗组(尤瑞克林+巴曲酶)32例、巴曲酶组31例、和对照组(常规治疗组)29例。观察3组治疗前后NIHSS评分(美国国立卫生院卒中量表)的变化。结果 3组治疗前NIHSS评分无差异,在治疗后14、28dNIHSS评分显示:联合治疗组神经功能明显改善,巴曲酶组有所改善,对照组恢复最差,3组间比较有统计学差异。所有病例无严重不良反应发生。结论尤瑞克林联合巴曲酶治疗急性大脑中动脉脑梗死安全、有效。

Objective To observe the therapetic effect of Urinary Kallidinogenase plus Batroxobin in treatment of acute middle cerebral artery infarction Methods Ninty-two patients with acute middle cerebral artery infarction were randomly assigned into combined treatment group（32cases）,batroxobin group（31cases） and control group（29cases）.All patients had been treated with the conventional neurological treatment.The NIHSS were evaluated before treatment and at 14 days and 28 days after treatment.Results The NIHSS score was no significant btween 3 groups before treatment.14days and 28days after treatment the symptom improvement score in Urinary Kallidinogenase plus.Batroxobin group was the highest,Batroxobin group was better and control group was the lowest.That means the improvement of neurological deficit in Urinary Kallidinogenase plus Batroxobin was excellent.Conclusion The report suggest that Urinary Kallidinogenase plus Batroxobin show effectiveness on the patients with acute middle cerebral artery infarction